# A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

> **NCT05716087** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 62 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Rocbrutinib

## Key facts

- **NCT ID:** NCT05716087
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-21
- **Primary completion:** 2024-12-05
- **Final completion:** 2026-06-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716087, "A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05716087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*